Successful Retreatment With ADOC Chemotherapy in Relapsed Thymic Carcinoma: Experiences in Two Cases

The optimal second-line chemotherapeutic regimen for thymic carcinoma remains uncertain and predictive factors for the response have not been identified. We encountered two cases of relapsed thymic carcinoma with recurrence 1.5 and 8 years after initial response to cisplatin/doxorubicin/vincristine/cyclophosphamide (ADOC) chemotherapy. Both cases were successfully retreated with ADOC. Our observations suggest that relapsed thymic carcinoma occurring a long treatment-free time from the initial response may be sensitive to the previous chemotherapy. We described two cases of relapsed thymic carcinoma successfully retreated with ADOC chemotherapy. Both patients had partial response to initial ADOC and long disease free times.

[1]  K. Kubo,et al.  Combination Chemotherapy with Doxorubicin, Vincristine, Cyclophosphamide, and Platinum Compounds for Advanced Thymic Carcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  K. Kubo,et al.  Salvage chemotherapy with amrubicin and platinum for relapsed thymic carcinoma: experience in six cases , 2010, Medical oncology.

[3]  B. Monk,et al.  Changing the Paradigm in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer: From Platinum Doublets to Nonplatinum Doublets and Adding Antiangiogenesis Compounds , 2009, International Journal of Gynecologic Cancer.

[4]  H. Ohmatsu,et al.  Performance status and sensitivity to first‐line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second‐line chemotherapy , 2008, Cancer.

[5]  K. Kubo,et al.  Second-line chemotherapy of platinum compound plus CPT-11 following ADOC chemotherapy in advanced thymic carcinoma: analysis of seven cases. , 2007, Anticancer research.

[6]  J. Ledermann,et al.  Management of platinum-sensitive recurrent ovarian cancer. , 2006, Seminars in oncology.

[7]  M. Inoue,et al.  Thymic carcinoma. Clinical institutional experience with 15 patients. , 2004, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[8]  H. Ohmatsu,et al.  Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma , 2003, Cancer.

[9]  B. Glisson.  Recurrent small cell lung cancer: update. , 2003, Seminars in oncology.

[10]  S. Suzuki,et al.  Chemotherapy of thymic carcinoma: analysis of seven cases and review of the literature. , 2001, Japanese journal of clinical oncology.

[11]  C. L. Chen,et al.  Thymic carcinoma: Ten years' experience in twenty patients , 1994 .

[12]  S. Suster,et al.  Thymic carcinoma. A clinicopathologic study of 60 cases , 1991, Cancer.

[13]  G Bonardi,et al.  Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.